Orforglipron UAE approval: what the evidence actually shows

What did @lovindubai actually say?

The creator claims the UAE has approved a new oral weight-loss medication called orforglipron (brand name Foundayo), making it the second country in the world to register it. They say it will be available from May 2026 by prescription only, under medical supervision, and stress it is "not a replacement for a healthy lifestyle." The delivery is measured and responsible. For a TikTok health claim, that is not nothing.

They also flag that it is a daily oral pill unlike current injectable GLP-1 treatments, and suggest it may be more affordable, though they correctly note pricing has not been confirmed. The core facts here are largely traceable to real regulatory developments, which sets this apart from most weight-loss content on the platform.

Does the science back this up?

Yes, mostly. Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide or tirzepatide, it does not require refrigeration or injection, which is a genuine practical advantage. The phase 3 ATTAIN trial data presented at the American Diabetes Association Scientific Sessions (2024) showed roughly 7-8% body weight reduction over 36 weeks in adults with obesity without diabetes, alongside meaningful reductions in HbA1c in diabetic populations.

A study by Rosenstock et al. (2023, New England Journal of Medicine) from earlier phase 2 trials showed dose-dependent weight loss of up to 14.7% over 36 weeks in people with type 2 diabetes. That is competitive with injectable options, though not quite at the ceiling set by tirzepatide. Gastrointestinal side effects, particularly nausea and vomiting, were common in trials, which the creator does not mention. That omission matters for informed decision-making.

What did they get wrong (or right)?

The claim that the UAE is "the second country in the world to register" orforglipron needs scrutiny. As of mid-2025, the US FDA had not yet approved orforglipron. Eli Lilly submitted a New Drug Application to the FDA in early 2025, with a decision expected later that year. If UAE approval preceded US approval, the "second country" framing implies another nation approved it first, which is plausible but unverified in public regulatory records available at time of writing.

The creator mispronounces both the brand name and generic name throughout, which is a minor but real issue when patients try to search for the drug or discuss it with a doctor. More substantively, the claim it will be "more affordable" is speculative. Eli Lilly has not published UAE pricing. GLP-1 medications have historically launched at high price points globally, and "more affordable than injectables" is not the same as accessible or covered by insurance. The creator does flag uncertainty here, which is fair, but the framing still leans optimistic without evidence.

• Prescription-only requirement: accurate and worth emphasizing
• Oral daily dosing vs. injectables: accurate
• UAE regulatory approval: plausible but unverified as "second country globally"
• May 2026 availability: plausible, unverifiable
• Affordability: speculative, presented too positively

What should you actually know?

Orforglipron represents a real shift in GLP-1 therapy if it delivers on phase 3 data at scale. The oral format removes a significant barrier for needle-averse patients and eliminates cold-chain logistics, which matters in markets with less robust pharmacy infrastructure. But "oral" does not mean "risk-free" or "mild." GLP-1 side effects, including nausea, vomiting, constipation, and potential pancreatitis risk, apply here too.

If you are in the UAE and interested in this medication, the creator is correct that this will require a proper clinical evaluation. A prescriber should review your cardiovascular history, any personal or family history of medullary thyroid carcinoma, and your current medications before considering any GLP-1 agent. The lifestyle point the creator makes is not just a disclaimer. Trial participants in Rosenstock et al. (2023) also received lifestyle counseling, and outcomes in real-world settings without that support are typically worse than trial results suggest.